ZBTB33 and breast carcinoma: Using this method, Singhal et al. showed the subcellular distribution of the multi-functional transcriptional regulator, Kaiso (ZBTB33), and its correlation with immune-suppressive characteristics and defined Kaiso’s value in breast cancer progression, which has potential as a predictive biomarker to guide future treatment, especially the immunotherapy using immune checkpoint inhibitors [66].